Effects of Xylooligosaccharides on the oxidant and physiological status in patients with type 2 diabetes mellitus

碩士 === 靜宜大學 === 食品營養研究所 === 94 === Bifidobacteria can digest xylooligosaccharide (XOS) to produce short chain fatty acid (ScFA), such as acetate, propionate and butyrate, which may affect the metabolism of blood sugar and lipids. The purpose of this study was to evaluate the effects of XOS in patien...

Full description

Bibliographic Details
Main Authors: Wei Chen, 陳瑋
Other Authors: Yin-Ching Chan
Format: Others
Language:zh-TW
Published: 2006
Online Access:http://ndltd.ncl.edu.tw/handle/p38q9t
Description
Summary:碩士 === 靜宜大學 === 食品營養研究所 === 94 === Bifidobacteria can digest xylooligosaccharide (XOS) to produce short chain fatty acid (ScFA), such as acetate, propionate and butyrate, which may affect the metabolism of blood sugar and lipids. The purpose of this study was to evaluate the effects of XOS in patients with type 2 diabetes mellitus. Diabetes outpatient subjects of Taichung Veterans General Hospital, with the HbA1c level between 7.0%-10.0% and triglyceride < 400 mg/dL were enrolled in this study. Patients were randomly divided into control (n=12) or experimental group (n=14). The experimental group were supplemented with 4g XOS per day for eight weeks, while the control group was replaced with the placebo. Anthropometric values, dietary intakes, hematological and biochemical parameters, oxidative status were evaluated before and after the experiment. The results showed that the anthropometric values and nutrient intakes did not differ during the experimental period. Blood glucose, HbA1c, fructosamine, serum total cholesterol, LDL-C and apolipoprotein B concentrations were significantly reduced after XOS supplementation. The serum ox-LDL concentration and the catalase activity of RBC also reduced, while the serum ScFA did not differ after the experiment. In conclusion, the supplementation of 4 g XOS per day for eight weeks could improve the blood glucose, serum lipids and oxidative status in type 2 diabetic patients.